Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial reported that intensive glucose control prevents end-stage kidney disease (ESKD) in patients with type 2 diabetes, but uncertainty about the balance between risks and benefits exists. Here, we examine the long-term effects of intensive glucose control on risk of ESKD and other outcomes. RESEARCH DESIGN AND METHODS: Survivors, previously randomized to intensive or standard glucose control, were invited to participate in post-trial follow-up. ESKD, defined as the need for dialysis or kidney transplantation, or death due to kidney disease, was documented overall and by baseline CKD stage, along with hypoglycemic episodes, major cardiovascular events, and death from other causes. RESULTS: A total of 8,494 ADVANCE participants were followed for a median of 5.4 additional years. In-trial HbA1c differences disappeared by the first post-trial visit. The in-trial reductions in the risk of ESKD (7 vs. 20 events, hazard ratio [HR] 0.35, P = 0.02) persisted after 9.9 years of overall follow-up (29 vs. 53 events, HR 0.54, P < 0.01). These effects were greater in earlier-stage CKD (P = 0.04) and at lower baseline systolic blood pressure levels (P = 0.01). The effects of glucose lowering on the risks of death, cardiovascular death, or major cardiovascular events did not differ by levels of kidney function (P > 0.26). CONCLUSIONS: Intensive glucose control was associated with a long-term reduction in ESKD, without evidence of any increased risk of cardiovascular events or death. These benefits were greater with preserved kidney function and with well-controlled blood pressure.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, there is a lag time of at least 2 years in type 2 diabetes to over 10 years in type 1 diabetes for the effects of intensive glucose control to manifest as improved eGFR outcomes (57,61,62).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [62]
In the citing paper
“Moreover, there is a lag time of at least 2 years in type 2 diabetes to over 10 years in type 1 diabetes for the effects of intensive glucose control to manifest as improved eGFR outcomes (59)(60)(61).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [61]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“Post-trial follow-up of the UK Prospective Diabetes Study (UKPDS) cohort of newly diagnosed patients with type 2 diabetes (7) and the Diabetes Control and Complications Trial (DCCT) cohort of young patients with type 1 diabetes (8) showed a sustained benefit for microvascular complications, beyond the period of intens…”
BackgroundSelf-citationBrenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493 · cited 1×
“Despite the implementation of “best practice” standards of care for lifestyle modification, blood pressure lowering, and renin-angiotensin-aldosterone system blockade, there remains a high level of progression to ESKD for those with diabetic kidney disease (4,5).”
BackgroundSelf-citationIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987 · cited 2×
“Despite the implementation of ‘best practice’ standards of care for lifestyle modification, blood pressure lowering and renin-angiotensin-aldosterone system (RAAS) blockade, there remains a high level of progression to ESKD for those with diabetic kidney disease (4, 5).”
BackgroundIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Andrassy, K. M. (2013) · Kidney International · doi:10.1038/ki.2013.243 · Cited by 2,496
Worldwide access to treatment for end-stage kidney disease: a systematic review
Liyanage, T., Ninomiya, T., Jha, V., Neal, B., Patrice, H. M., Okpechi, I., Zhao, M.-H., Lv, J., Garg, A. X., Knight, J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61601-9 · Cited by 2,339
Self-citationIsmail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428
Cited by
Items 101–200 of 239
Zoungas, S. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13968 · Cited by 17
“for diabetic kidney disease persisted long after return to usual care.(16,20)”
BackgroundSelf-citationOhkuma, T., Zoungas, S., Jun, M., Lisheng, L., Mancia, G., Marre, M., Rodgers, A., Williams, B., Woodward, M., Chalmers, J. P., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13878 · Cited by 15
“glucose-lowering, particularly with respect to premature death in patients with chronic kidney disease (CKD).(2,3) Although, dose adjust-”
BackgroundSelf-citationShi, X., Qu, T., Pottelbergh, G. V., van den Akker, M., & Moor, B. D. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.730748 · Cited by 14
Arici, M., ALTUN, B., Araz, M., Atmaca, A. A., Demir, T., Ecder, T., Güz, G., Yavuz, D. G., Yildiz, A., & Yilmaz, T. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1384454 · Cited by 19
PAIT-survey—Prevalence of albuminuria in patients with diabetes and hypertension in Turkey
Fıcı, F., Bakir, E. A., Beyaz, Ş., Makel, W., & Robles, N. R. (2018) · Primary care diabetes · doi:10.1016/j.pcd.2018.08.008 · Cited by 13
Oshima, M., Hara, A., Toyama, T., Jun, M., Pollock, C. A., Jardine, M., Harrap, S. B., Poulter, N. R., Cooper, M. E., Woodward, M., et al. (2020) · Kidney International Reports · doi:10.1016/j.ekir.2020.10.039 · Cited by 13
Self-citationCervantes, J., Koška, J., Kramer, F., Akilesh, S., Alpers, C. E., Mullick, A. E., Reaven, P. D., & Kanter, J. E. (2024) · JCI Insight · doi:10.1172/jci.insight.177268 · Cited by 15
Itoh, H., Kurihara, I., Miyashita, K., & Tanaka, M. (2017) · Hypertension Research · doi:10.1038/hr.2016.192 · Cited by 11
Preventing the development and progression of diabetic kidney disease: Where do we stand?
Zagkotsis, G., Markou, M. I., Paschou, E., Papanikolaou, P., & Sabanis, N. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.03.012 · Cited by 14
Alicic, R. Z., Johnson, E. J., & Tuttle, K. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52978-5.00003-3 · Cited by 12
Why We Need Sex-Gender Medicine: The Striking Example of Type 2 Diabetes
Seghieri, G., Franconi, F., & Campesi, I. (2022) · Diabetology · doi:10.3390/diabetology3030034 · Cited by 11
Lu, J., Zhao, W., Chen, T., Xu, Z., Sun, X., Xie, H., An, Y., Zeng, C., Hu, G., Xie, G., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-001166 · Cited by 11
Das, A. K., Saboo, B., Chawla, R., Aravind, S. R., Rajput, R., Singh, A. K., Mukherjee, J. J., Jhingan, A. K., Shah, P., Deshmukh, V. C., et al. (2023) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-023-01192-6 · Cited by 18
“Furthermore, gliclazide, compared to glimepiride, conferred protection from renal complications in certain patients even after 6 years of follow-up [41].”
BackgroundPolavarapu, N. K., Kale, R. M., Sethi, B. K., Sahay, R. K., Phadke, U., Ramakrishnan, S., Mane, A., Mehta, S. C., & Shah, S. P. (2020) · Drugs - Real World Outcomes · doi:10.1007/s40801-020-00206-7 · Cited by 13
Recent advances in the pharmacotherapeutic management of diabetic kidney disease
Block, T. J., Batu, D., & Cooper, M. E. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2054699 · Cited by 10
“ESKD, particularly in those with preserved renal function and well-controlled blood pressure [8].”
BackgroundSelf-citationThe SONAR study—is there a future for endothelin receptor antagonists in diabetic kidney disease?
Cahn, A., Cernea, S., & Raz, I. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.09.117 · Cited by 9
Tangri, N., Singh, R. K., Chen, Y., Betts, K. A., Farag, Y. M. K., Beeman, S. C., Du, Y., Kong, S. X., Williamson, T. E., Li, Q., et al. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004854 · Cited by 11
Self-citationPanduru, N. M., Nistor, I., Groop, P., Biesen, W. V., Farrington, K., & Covic, A. C. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx021 · Cited by 10
Kılıçkap, M., Kozluca, V., Tan, T. S., & Akbulut, İ. M. (2023) · Angiology · doi:10.1177/00033197231183229 · Cited by 12
Wyatt, C. M., & Cattran, D. C. (2016) · Kidney International · doi:10.1016/j.kint.2016.05.002 · Cited by 7
Novel cardiovascular metabolic risk factor mechanisms and therapeutic opportunities
Evans, P. C., Vilahur, G., Kleinbongard, P., Osto, E., Remme, C. A., Madonna, R., Aksentijević, D., Sourij, H., Davidson, S. M., Santovito, D., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag116 · Cited by 10
Kim, H., Wang, D., Chalmers, J. P., Jun, M., Zoungas, S., Marre, M., Hamet, P., Harrap, S. B., Mancia, G., Poulter, N. R., et al. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13083 · Cited by 8
“At the end of the ADVANCE trial, the blood pressuring-lowering intervention lowered incidence of total renal events, and intensive glucose control lowered incidence of nephropathy.(30,31,35) It has been shown that angiotensin-converting enzyme (ACE) inhibitors have long-term benefits on kidney disease progression.”
BackgroundSelf-citationSlowing Progression of Chronic Kidney Disease
Drawz, P. E., Hostetter, T. H., & Rosenberg, M. E. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815876-0.00057-7 · Cited by 10
Organ-Specific Glucose Uptake: Does Sex Matter?
Gandhi, A., Tang, R., Seo, Y., & Bhargava, A. (2022) · Cells · doi:10.3390/cells11142217 · Cited by 6
“In the ADVANCE-On trial [29], gliclazide successfully controlled blood glucose levels in men, but not women.”
BackgroundAssociation of blood glucose and renal end points in advanced diabetic kidney disease
Kornelius, E., Lo, S., Huang, C., Wang, Y., & Yang, Y. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108011 · Cited by 7
Awdishu, L., Moore, T., Morrison, M., Turner, C., & Trzebinska, D. (2019) · Pharmacy · doi:10.3390/pharmacy7030083 · Cited by 9
Lee, A. K., Steinman, M. A., & Lee, S. J. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001624 · Cited by 6
Nicholas, S. B., & Tuttle, K. R. (2020) · Nephrology Self-Assessment Program · doi:10.1681/nsap.2020.19.2.5 · Cited by 6
ACCORDION: Ensuring That We Hear the Music Clearly
Wong, M. G., Heerspink, H. J. L., & Perkovic, V. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11370918 · Cited by 6
Self-citationLiew, A., Bavanandan, S., Hao, C., Lim, S. K., Prasad, N., Sahay, M., Susantitaphong, P., Roberts, V., Wijewickrama, E. S., Wong, M. G., et al. (2025) · Nephrology · doi:10.1111/nep.70030 · Cited by 7
Self-citationNavarro‐González, J. F., de Isla, L. P., Molina, G. C., Brito-Sanfiel, M. Á., Galindo, D. E. B., Olmedo, L. Á. C., Mauricio, D., Tofé, S., Barro, J. A. B., Rubio-Almanza, M., et al. (2025) · Kidney Diseases · doi:10.1159/000547604 · Cited by 7
“Although several risk factors and aspects of CKD progression can potentially be modified through lifestyle changes and therapeutic interventions, particularly when implemented early [11–13], detecting CKD in its initial stages remains challenging due to its usually asymptomatic nature [14].”
Xu, J., Xue, Y., Chen, Q., Han, X., Cai, M., Tian, J., Jin, S., & Lu, H. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.928825 · Cited by 8
Sodium-Glucose Transporter Inhibition in Adult and Pediatric Patients with Type 1 Diabetes Mellitus
Vitale, R. J., & Laffel, L. M. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.05.001 · Cited by 7
Антонова, К. В., Лагода, О. В., & Tanashyan, M. М. (2022) · Diabetes Mellitus · doi:10.14341/dm12840 · Cited by 7
Oliver, N. S., Chow, E., Luk, A. O. Y., & Murphy, H. R. (2023) · Diabetic Medicine · doi:10.1111/dme.15038 · Cited by 6
Tummalapalli, S. L., Struthers, S. A., White, D. L., Beckrich, A. L., Brahmbhatt, Y. G., Erickson, K. F., Garimella, P. S., Gould, E. R., Gupta, N., Lentine, K. L., et al. (2023) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000163 · Cited by 5
Molitch, M. E., Tripputi, M., Levey, A. S., Crandall, J. P., Dabelea, D., Herman, W. H., Knowler, W. C., Orchard, T. J., Schroeder, E. B., Srikanthan, P., et al. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108556 · Cited by 6
Renal Histologic Findings in Necropsies of Type 2 Diabetes Mellitus Patients
D’Marco, L., Puchades, M. J., Escudero-Saiz, V. J., Giménez-Civera, E., Terrádez-Mas, L., Moscardó, A., Carbonell‐Asins, J. A., Pérez-Bernat, E., Torregrosa, I., Moncho, F., et al. (2022) · Journal of Diabetes Research · doi:10.1155/2022/3893853 · Cited by 5
“This has also been demonstrated in kidney biopsies from DN-affected patients, where 85% displayed arteriolar hyalinosis and 60% arteriolosclerosis [16]; this condition can also affect the arteries, with a preponderant role in glomerular hemodynamic changes.”
BackgroundThe long-term benefits of early intensive therapy in chronic diseases—the legacy effect
Zoccali, C., Mallamaci, F., Tripepi, G. L., Fu, E. L., Stel, V. S., Dekker, F. W., & Jager, K. J. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad186 · Cited by 6
“Notably, in the post-trial follow-up, the reduced risk for kidney failure was maintained and attained statistical significance at 10 years ( risk reduction –66%; P = .007 ) , again despite the convergence of HbA1c levels after the trial ended [ 4 ].”
BackgroundGlycemic Key Metrics and the Risk of Diabetes-Associated Complications
Kohnert, K., Heinke, P., Zander, E., Vogt, L., & Salzsieder, E. (2016) · Romanian Journal of Diabetes Nutrition and Metabolic Diseases · doi:10.1515/rjdnmd-2016-0047 · Cited by 5
Approach to the treatment of diabetes in the elderly
Altuntaş, Y. (2019) · SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital · doi:10.14744/semb.2019.00868 · Cited by 13
Hameed, S., Kumar, A. J., Manohar, M., Singh, A., & Mohan, L. (2024) · International Journal of Pharmaceutical Sciences Review and Research · doi:10.47583/ijpsrr.2024.v84i03.025 · Cited by 4
“24,25 The current research was designed to compare the efficacy and safety of empagliflozin and linagliptin as add-on therapies to insulin in patients with Type 2 Diabetes Mellitus (T2DM) and chronic kidney disease, keeping in mind the results of previous studies and strengthening the evidence for…”
Ensuring Patient Safety During the Transition to ESRD
Wagner, L.-A., & Fink, J. C. (2017) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2016.12.009 · Cited by 4
Li, P., Kianmehr, H., Guan, D., Kulshreshtha, A., Narayan, K. M. V., Ali, M. K., Umpierrez, G. E., Hu, X., Fonseca, V. A., Shi, L., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15744 · Cited by 5
O’Hara, D. V., Neuen, B. L., & Jardine, M. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00809-x · Cited by 4
Cheung, J. T. K., Yang, A., Wu, H., Lau, E. S. H., Shi, M., Kong, A. P. S., Ronald, C. W., Luk, A. O. Y., Chan, J. C. N., & Chow, E. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110203 · Cited by 4
Block, T. J., & Cooper, M. E. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104178 · Cited by 4
Self-citationZhu, L., Bell, K., & Hayen, A. D. (2019) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2019.05.010 · Cited by 6
Nguyen-Thi, H.-Y., Nguyen, N. T. Q., Le, N. D. T., Beillat, M., & Ethgen, O. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.562023 · Cited by 3
Zhuo, C., Lin, C., Zhou, C., Gao, X., Shao, H., Fang, T., Tian, H., Ding, L., & Liu, M. R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.759262 · Cited by 5
Newer and novel antidiabetic drug classes across the cardiovascular–kidney–metabolic continuum
Stefanakis, K., Karakasis, P., Vasdeki, D., Popovic, D. S., Patoulias, D., Rizzo, M., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag022 · Cited by 6
Luo, Y., Wang, X., Ni, W.-J., Ding, B., Xu, X., Ye, L., Ma, J., & Zhu, J. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0502-5 · Cited by 4
New hypoglycemic agents and the kidney: what do the major trials tell us?
Smyth, B. J., & Perkovic, V. (2018) · F1000Research · doi:10.12688/f1000research.16135.1 · Cited by 4
“Interestingly, the risk of decline in eGFR to 30 mL/minute/1.73 m 2 was not affected by tighter glycemic control (HR 1.16 [95% CI 0.93, 1.44]), and, while the ADVANCE trial found a reduced risk of ESKD in participants randomized to tight control 10 , this was not seen across the other trials 9 .”
BackgroundInfluentialSelf-citationDiabetes and Cerebrovascular Disease
Lioutas, V., & Palaiodimou, L. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_18 · Cited by 3
Zhang, Z., Liu, Y., Qian, J., Jiang, W., Cao, L., Li, Z., Chen, H., & Liu, S. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1400939 · Cited by 3
Norris, K. C., Williams, S. F., Nicholas, S. B., & Agodoa, L. Y. C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804311-0.00019-4 · Cited by 8
Modern Sulfonylureas Strike Back – Exploring the Freedom of Flexibility
Kalra, S., & Khandelwal, D. (2018) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2018.14.2.20 · Cited by 4
“Similar flexibility is noted in the renal arena, where early intensive glycaemic control with gliclazide MR is found to be useful, especially in terms of reducing the risk of end stage renal disease.(5) Its use is associated with a legacy benefit, as demonstrated in the ADVANCE ON trial.”
BackgroundMethodRaman, R. B., Kumar, D., & Roushan, R. (2022) · International Journal of Pharmaceutical Sciences Review and Research · doi:10.47583/ijpsrr.2022.v77i02.022 · Cited by 2
“23 It is essential to find a pharmacotherapy that is fast acting and effective in achieving proper glycaemic control and thus delaying the onset and progression of CKD.(24,25) Keeping these findings of earlier researches in mind and to further strengthen the evidence for the use of empagliflozin or linagliptin in high…”
ResultInfluentialImpact of the COVID-19 pandemic on the outcomes of Indonesian chronic disease management program
Salamah, S., Ramadhani, R., Arfiana, M. R., Syamsuri, I., Nugraha, D., Illavi, F., Khafiyya, A. N., Dewayani, A., Rokhman, M. R., & Alkaff, F. F. (2023) · Electronic Journal of General Medicine · doi:10.29333/ejgm/13661 · Cited by 5
“Indeed, studies have shown that renal function is tightly associated with glycemic control [52, 53].”
BackgroundJiao, T., Kianmehr, H., Lin, Y., Li, P., Ospina, N. S., Ghayee, H. K., Ruzieh, M., Fonseca, V. A., Shi, L., Zhang, P., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15453 · Cited by 3
“34 The benefit of intensive glucose control on individuals with normal eGFR may stem from timely treatment before the advancement of diabetic kidney disease.”
BackgroundRecommended procedures for diabetic kidney disease 2021
Pelikánová, T., Viklický, O., Rychlík, I., Saudek, F., Tesař, V., Haluzík, M., Kvapil, M., Racek, J., & Zima, T. (2021) · Klinická biochemie a metabolismus · doi:10.61568/kbm.2021.016 · Cited by 4
Aziz, S., Harun, S. N., & Ghadzi, S. M. S. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70104 · Cited by 2
“As previous findings of intensive glucose management have shown better effects on kidney function and decrease in all-cause mortality, still the range of FBS that can be targeted in the general population is controversial and may need to be individualized [33, 34].”
Lo, C., & Zoungas, S. (2017) · BMJ Evidence-Based Medicine · doi:10.1136/ebmed-2017-110806 · Cited by 2
Self-citationMonnier, L., & Colette, C. (2018) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(18)30106-8 · Cited by 2
Rosas-Saucedo, J., Rosas-Guzmán, J., Mesa-Pérez, J. A., González-Ortíz, M., Martínez‐Abundis, E., González-Suárez, R., Sinay, I. R., & Lyra, R. (2019) · Alad · doi:10.24875/alad.19000375 · Cited by 3
Soliman, A. R., Soliman, H., & Naguib, M. (2021) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2021.5364 · Cited by 2
“Indeed, long-term glycemic control reduces the risk of ESRD [9].”
BackgroundPathogenesis of diabetic kidney disease
Tang, S. C. W., Chan, A. T. P., Yiu, W. H., & Lai, K. N. (2021) · Diabetic Nephropathy · doi:10.2478/dine-2021-0004 · Cited by 3
Wang, N., Zoungas, S., & Chalmers, J. P. (2022) · La Presse Médicale · doi:10.1016/j.lpm.2022.104160 · Cited by 3
Self-citationHirai, K., Imamura, S., Ookawara, S., Hirai, A., & Morishita, Y. (2017) · Nephro-Urology Monthly · doi:10.5812/numonthly.55058 · Cited by 3
“In patients with diabetic nephropathy, appropriate management of blood glucose level is important to delay the progression to end-stage renal disease and prevent the development of cardiovascular disease (3, 4).”
Diabetes mellitus Typ 2: Wie schützen wir die Nieren am besten?
Brenner, S., & Wanner, C. (2019) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-0662-1919 · Cited by 2
“Durch die intensivierte Blutzuckerkontrolle (Ziel-HbA1c < 7 %) lassen sich weder Mortalität noch kardiovaskuläre Ereignisse reduzieren, jedoch gelingt wohl im Langzeitverlauf die Verminderung mikrovaskulärer Veränderungen [3].”
BackgroundInfluentialRaghubeer, S., Matshazi, D. M., Motshwari, D. D., Weale, C. J., Erasmus, R. T., & Matsha, T. E. (2022) · Biomarkers in disease · doi:10.1007/978-3-030-81303-1_61-1 · Cited by 2
Diabetic Kidney Disease: Increasing Hope with Transformative Therapies
Rosas, S. E., & Nasser, S. (2023) · Springer eBooks · doi:10.1007/978-3-031-42045-0_4 · Cited by 1
Sacchetta, L., Tricò, D., & Solini, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-88426-6.00011-7 · Cited by 1
The place of gliclazide MB in modern treatment strategies for patients with type 2 diabetes mellitus
Petunina, N. A., Martirosian, N. S., Валерьевна, Г. Е., Эдуардовна, Т. М., Кузина, И. А., Олеговна, Щ. А., & Акрамовна, Э. Э. (2024) · Diabetes Mellitus · doi:10.14341/dm13184 · Cited by 2
Optimizing Type 2 Diabetes Management: The Efficacy and Safety of Gliclazide in Clinical Practice
Mohan, V., Makkar, B. M., Saboo, B., Jagadisha, A., Chawla, M. S., Deshpande, N., Goyal, V. K., & Kapoor, R. (2025) · Journal of Diabetology · doi:10.4103/jod.jod_50_25 · Cited by 3
Jermendy, G. (2018) · Orvosi Hetilap · doi:10.1556/650.2018.31041 · Cited by 1
Efficacy and Safety of GLP-1 Agonists in Chronic Kidney Disease: A Case Series
Awdishu, L., & Morello, C. M. (2018) · Clinical Medical Reviews and Case Reports · doi:10.23937/2378-3656/1410242 · Cited by 1
“The median number of co-morbidities was 8 (5-14) with hypertension, hyperlipidemia and cardiovascular complications most common.”
BackgroundGlycemic Control and Future Perspectives for Treatment
Miyamoto, S., & Shikata, K. (2020) · Springer eBooks · doi:10.1007/978-981-15-9301-7_6 · Cited by 1
Diabetic Kidney Disease Represents a Locus of Opportunity
ECELBARGER, C. A. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.650503 · Cited by 1
“Despite an abundance of evidence that hyperglycemia is upstream of a plethora of pathways that have been shown to be damaging to the kidney, there is little evidence to show that strict glucose control alone, in the clinical setting, can reverse pre-existing DN (Wong et al., 2016).”
BackgroundHirai, K., Nonaka, H., Ueda, M., Morino, J., Kaneko, S., Minato, S., Mutsuyoshi, Y., Yanai, K., Ishii, H., Matsuyama, M., et al. (2021) · Pragmatic and Observational Research · doi:10.2147/por.s314409 · Cited by 1
“Therefore, optimal glycemic control is necessary to prevent the development and progression of diabetic kidney disease.(3) However, the use of blood glucose-lowering agents is restricted in patients with advanced diabetic kidney disease because renal dysfunction attenuates the clearance and metabolism of these drugs a…”
BackgroundKelly, J., & Solomon, R. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_17 · Cited by 2
Prevención de la enfermedad renal crónica en personas con diabetes mellitus
Simarro, F. L. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.renal.art6 · Cited by 3
Elkeraie, A. F., Al-Ghamdi, S., Abu‐Alfa, A. K., Al-Otaibi, T., Alsaedi, A. J., AlSuwaida, A., Arıcı, M., Ecder, T., Ghnaimat, M. A., Hafez, M., et al. (2024) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s430532 · Cited by 1
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4643-7 · Cited by 3
Zhao, N., Zhang, Y., Liu, P., Zhang, X., Zhang, Z., Ou, W., Dong, A., Chang, Y., Chen, S., Wang, G., et al. (2024) · Endocrine · doi:10.1007/s12020-024-04119-1 · Cited by 1
Wang, Y., Wen, Q., Lu, Y., Yang, J., Huang, N., & Chen, W. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16111 · Cited by 1
Раннє призначення інсуліну при цукровому діабеті 2-го типу: плюси і мінуси
Jargin, S. V. (2021) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.17.2.2021.230572 · Cited by 1
Workplace Outreach Program Improves Management of Chronic Kidney Disease
Iakoubova, O. A., Tong, C. H., Rowland, C. M., Arellano, A. R., Bare, L. A., Fragala, M. S., & Birse, C. E. (2021) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0000000000002475 · Cited by 1
Raghubeer, S., Matshazi, D. M., Motshwari, D. D., Weale, C. J., Erasmus, R. T., & Matsha, T. E. (2022) · Biomarkers in disease · doi:10.1007/978-3-031-08014-2_61 · Cited by 2
A gliklazid MR helye a 2-es típusú diabetes jelen antidiabetikus kezelésében
Winkler, G. (2022) · Diabetologia Hungarica · doi:10.24121/dh.2022.3 · Cited by 1
Sulfonylureas at the Glomerular Battlefield
Kalra, S., Khandelwal, D., Bajaj, S., & Das, A. K. (2018) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2018.14.2.15 · Cited by 1
Management of Diabetes 100 Years After the Discovery of Insulin: Nuances for the Kidney
Battistella, M. (2021) · Kidney Medicine · doi:10.1016/j.xkme.2021.02.001 · Cited by 1
“Kidney Med Vol 3 | Iss 2 | March/April 2021 kidney failure; the effects were more pronounced in earlier stages of diabetic kidney disease.(8)”
BackgroundIs clinical trial data showing positive progress for the treatment of diabetic kidney disease?
Tan, S. K., & Cooper, M. E. (2023) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2023.2277762 · Cited by 1
“…and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial and the follow-up ADVANCE-ON study echoed this metabolic memory effect, as well as demonstrating a long-term reduction in ESKD risk, especially in patients with preserved kidney function and well-controlled hypertension [13,14].”
BackgroundSelf-citation18. Recent Progresses in Diabetic Nephropathy
Wada, T. (2016) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.105.131b
Ramadan fasting in diabetes-exercise in problem-solving
Saboo, B. (2017) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2017.05.003
Diabetische Nephropathie - Grundlagen und Hintergründe
Löwe, P., Chatzikyrkou, C., & Mertens, P. R. (2017) · Diabetes aktuell · doi:10.1055/s-0043-121794
“[8] Wong MG, Perkovic V, Chalmers J et al.”
BackgroundGlycemic Targets and Prevention of Chronic Complications
Cernea, S., Cahn, A., & Raz, I. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_14-1
Metabolic Control of GP-led Hypertensive Type 2 Diabetes Patients on Oral Antidiabetic Drugs
Kirov, L. K., Mihai, B., Emil, M., Dimitrov, H., & Nevena, I. (2018) · Diabetes & its Complications · doi:10.33425/2639-9326.1027
“Recent intervention trials such as STENO-2 and ADVANCE-ON showed that intensive multifactorial treatment of diabetes could heavily reduce the incidence and progression of both micro- and macrovascular complications [5-7].”
MethodRenal protection: What have we learnt from ADVANCE about kidney disease in type 2 diabetes?
Knudsen, S. T., & Cooper, M. E. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13917 · Cited by 3
“treatment group for the subsequent prevention of ESRD by in-trial intensive glucose-lowering.(19,20) Conversely, significant heterogeneity for this effect size was observed for systolic BP and CKD.”
BackgroundMethodSelf-citation18. Recent Progresses in Diabetic Nephropathy
Wada, T. (2016) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.105.1870
Metadata
- Authors
- Wong, M. G., Perkovic, V., Chalmers, J., Woodward, M., Li, Q., Cooper, M. E., Hamet, P., Harrap, S., Heller, S., MacMahon, S., Mancia, G., Marre, M., Matthews, D., Neal, B., Poulter, N., Rodgers, A., Williams, B., & Zoungas, S.
- Affiliations
- The University of Sydney (AU)
- Baker Heart and Diabetes Institute (AU)
- Centre Hospitalier de l’Université de Montréal (CA)
- The Royal Melbourne Hospital (AU)
- National Health Service (GB)
- IRCCS Istituto Auxologico Italiano (IT)
- Hôpital Bichat-Claude-Bernard (FR)
- University of Oxford (GB)
- Imperial College London (GB)
- University College London (GB)
- Corresponding author
- Perkovic, Vlado
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-03-22
- Volume
- 39
- Issue
- 5
- Pages
- 694-700
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2309242694
- Semantic Scholar
- 0dde5dd296b76622b14c9be052e0e64aac7208f9
- Cited by
- 240
- References
- 19
- Citations by year
- 2026: 12 · 2025: 15 · 2024: 19 · 2023: 23 · 2022: 28 · 2021: 27 · 2020: 23 · 2019: 21 · 2018: 37 · 2017: 24 · 2016: 11
- FWCI
- 31.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0509-10222, NF-SI-0514-10011)
- Medical Research Council (MC_PC_13090)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- tight glycemic control, end-stage renal disease, type 2 diabetes, ADVANCE trial, post-trial follow-up, chronic kidney disease, HbA1c, hypoglycemia, cardiovascular events, cardiovascular mortality, blood pressure, long-term outcomes
- MeSH terms
- Aged, Antihypertensive Agents, Blood Glucose, Blood Pressure, Diabetes Mellitus, Type 2, Drug Combinations, Female, Follow-Up Studies, Gliclazide, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Indapamide, Kidney Failure, Chronic, Male, Middle Aged, Treatment Outcome, Perindopril
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.